Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens

Journal of Steroid Biochemistry and Molecular Biology

Volumn 138, Issue , 2013, Pages 359-367

  Labrie, Fernand ^a,b   Martel, Céline ^a   Bérubé, René ^a   Côté, Isabelle ^a   Labrie, Claude ^a,b   Cusan, Leonello ^a,b   Gomez, José Luis ^b  

^a EndoCeutics   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Dehydroepiandrosterone; Dyspareunia; Intracrinology; Intravaginal prasterone; Local administration; Vulvovaginal atrophy

Indexed keywords

17BETA DIOL GLUCURONIDE; ANDROGEN; ANDROSTANOLONE; ANDROSTERONE; ANDROSTERONE GLUCURONIDE; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; PRASTERONE; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; LIMIT OF QUANTITATION; POSTMENOPAUSE; TESTOSTERONE BLOOD LEVEL; VAGINA ATROPHY;

DEHYDROEPIANDROSTERONE; DYSPAREUNIA; INTRACRINOLOGY; INTRAVAGINAL PRASTERONE; LOCAL ADMINISTRATION; VULVOVAGINAL ATROPHY;

ADMINISTRATION, INTRAVAGINAL; AGED; ANDROGENS; DEHYDROEPIANDROSTERONE; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; TESTOSTERONE;

EID: 84883201802     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2013.08.002     Document Type: Article

References (27)

1. F. Labrie, C. Martel, and J. Balser Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary Menopause 18 2011 30 43
2. D.W. Sturdee, and N. Panay Recommendations for the management of postmenopausal vaginal atrophy Climacteric 13 2010 509 522
3. R.E. Nappi, and M. Kokot-Kierepa Women's voices in the menopause: results from an international survey on vaginal atrophy Maturitas 67 2010 233 238
4. M.B. Mac Bride, D.J. Rhodes, and L.T. Shuster Vulvovaginal atrophy Mayo Clin. Proc. 85 2010 87 94
5. C. Lynch Vaginal estrogen therapy for the treatment of atrophic vaginitis J. Womens Health (Larchmt) 18 2009 1595 1606
6. F. Labrie Intracrinology Mol. Cell. Endocrinol. 78 1991 C113 C118
7. F. Labrie, V. Luu-The, A. Belanger, S.X. Lin, J. Simard, G. Pelletier, and C. Labrie Is dehydroepiandrosterone a hormone J. Endocrinol. 187 2005 169 196
8. F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, J.L. Gomez, G. Girard, M. Baron, N. Ayotte, M. Moreau, R. Dube, I. Cote, C. Labrie, L. Lavoie, R. Berube, P. Belanger, L. Berger, L. Gilbert, C. Martel, and J. Balser Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration Menopause 16 2009 897 906
9. F. Labrie, L. Cusan, J.L. Gomez, I. Cote, R. Berube, P. Belanger, C. Martel, and C. Labrie Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women J. Steroid Biochem. Mol. Biol. 111 2008 178 194
10. F. Labrie, L. Cusan, J. Gomez, I. Cote, R. Berube, and P. Belanger Corrigendum to effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women J. Steroid Biochem. Mol. Biol. 112 2008 169
11. A.M. Traish, H.P. Kang, F. Saad, and A.T. Guay Dehydroepiandrosterone (DHEA) - a precursor steroid or an active hormone in human physiology J. Sex Med. 8 11 2011 2960 2982 (quiz 2983)
12. F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, J.L. Gomez, G. Girard, M. Baron, N. Ayotte, M. Moreau, R. Dubé, I. Côté, C. Labrie, L. Lavoie, L. Berger, L. Gilbert, C. Martel, and J. Balser Intravaginal dehydroepiandrosterone (prasterone), a physiological and highly efficient treatment of vaginal atrophy Menopause 16 2009 907 922
13. F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, J.L. Gomez, G. Girard, M. Baron, N. Ayotte, M. Moreau, R. Dube, I. Cote, C. Labrie, L. Lavoie, L. Berger, L. Gilbert, C. Martel, and J. Balser Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women Menopause 16 2009 923 931
14. F. Labrie, A. Belanger, P. Belanger, R. Berube, C. Martel, L. Cusan, J. Gomez, B. Candas, I. Castiel, V. Chaussade, C. Deloche, and J. Leclaire Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women J. Steroid Biochem. Mol. Biol. 99 2006 182 188 (Pubitemid 43766081)
15. F. Labrie, L. Cusan, J.L. Gomez, I. Cote, R. Berube, P. Belanger, C. Martel, and C. Labrie Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women Menopause 16 2009 30 36
16. J. Suckling, A. Lethaby, and R. Kennedy Local oestrogen for vaginal atrophy in postmenopausal women Cochrane Database Syst. Rev. 4 2006 CD001500
17. W.H. Utian, D.F. Archer, G.A. Bachmann, C. Gallagher, F. Grodstein, J.R. Heiman, V.W. Henderson, H.N. Hodis, R.H. Karas, R.A. Lobo, J.E. Manson, R.L. Reid, P.J. Schmidt, and C.A. Stuenkel Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society Menopause 15 4 Pt 1 2008 584 602
18. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance For Industry, Labeling Guidance for Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Prescribing Information for Health Care Providers and Patient Labeling 2004 Available at: www.fda.gov/OHRMS/DOCKETS/98fr/1998d-0834-gdl0003.pdf
19. M.H. Birkhauser, N. Panay, D.F. Archer, D. Barlow, H. Burger, M. Gambacciani, S. Goldstein, J.A. Pinkerton, and D.W. Sturdee Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause Climacteric 11 2008 108 123 (Pubitemid 351451114)
20. M. Eugster-Hausmann, J. Waitzinger, and D. Lehnick Minimized estradiol absorption with ultra-low-dose 10 micrograms 17beta-estradiol vaginal tablets Climacteric 13 2010 219 227
21. K. Nilsson, and G. Heimer Low-dose oestradiol in the treatment of urogenital oestrogen deficiency - a pharmacokinetic and pharmacodynamic study Maturitas 15 1992 121 127
22. M. Notelovitz, S. Funk, N. Nanavati, and M. Mazzeo Estradiol absorption from vaginal tablets in postmenopausal women Obstet. Gynecol. 99 2002 556 562 (Pubitemid 34246288)
23. J. Simon, L. Nachtigall, R. Gut, E. Lang, D.F. Archer, and W. Utian Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet Obstett. Gynecol. 112 2008 1053 1060
24. J.A. Simon, K.Z. Reape, S. Wininger, and H. Hait Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women Fertil. Steril. 90 2008 1132 1138
25. G. Bachmann, R.A. Lobo, R. Gut, L. Nachtigall, and M. Notelovitz Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial Obstet. Gynecol. 111 2008 67 76
26. S.O. Skouby, F. Al-Azzawi, D. Barlow, J. Calaf-Alsina, E. Ertungealp, A. Gompel, A. Graziottin, D. Hudita, A. Pines, S. Rozenberg, G. Samsioe, and J.C. Stevenson Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy Maturitas 51 2005 8 14 (Pubitemid 40692593)
27. F. Labrie DHEA after menopause - sole source of sex steroids and potential sex steroid deficiency treatment Menopause Manage. 19 2010 14 24